The performance of companies tied to the drug's legacy presents a challenging investment picture . While the initial boom generated substantial profits , generic alternatives have significantly diminished sales . Investing in related pharmaceutical firms now requires a thorough assessment of patent rights , evolving healthcare trends , and the pros